Загрузка...
CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
In spite of the efficacy of Her2-targeted therapies, recurrence and progression remain a challenge for treatment of Her2 positive breast cancer. CDK4/6 controls pathway downstream of Her2, Inhibition of these kinases could represent an important therapeutic approach to augment the effectiveness of s...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Impact Journals LLC
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4162138/ https://ncbi.nlm.nih.gov/pubmed/25221644 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|